The relative fold change in FOXD3 mRNA expression was significantly lower in B-ALL patients compared to controls (0.1626 vs. 1.06; p < 0.0001), consistent with the observed overexpression of VISTA (Fig. 4). This evidence concerns the gene FOXD3 and precursor B-cell acute lymphoblastic leukemia.